South and Central America Brain Cancer Diagnostics Market

Market Introduction

Brain cancers are caused due to extracellular growth of the cells in the brain that causes tumors. The tumor includes primary brain tumors and secondary brain tumors. Primary brain tumors are formed in the brain and do not spread to other body parts, whereas secondary tumors, also known as metastases, are those cancers that began in another part of the body.  Brain tumors are categorized into 40 major types that are further classified into two major groups, including benign, i.e., slow-growing and have less possibility to spread, and malignant, i.e., cancerous, and more likely to spread.

Thus, the increase in prevalence of brain cancer is expected to create a significant demand for brain cancer diagnostics in the coming years, which is further anticipated to drive the brain cancer diagnostics market.

The COVID? 19 pandemic is a critical test for the already overburdened and underfunded public healthcare systems of South and Central America. It suffers from severe inequalities. With a vast population living in poverty, South and Central America continuously face widespread health problems due to overcrowding, limited sanitation, food insecurity, and unpredictable environmental conditions. Underfunded state?run hospitals are the only source of medical care in the region. Brazil is in a critical situation due to COVID-1. Lack of resources is creating more challenges in the region, hampering the growth of the brain cancer diagnostics market. All these factors will restrict the distribution and adoption of diagnostics products and services which will restrict the market growth. However, as the vaccination continues to these countries, the various market players in this region will again start focusing on development of brain cancer diagnostics and increase their distribution of products. Hence impact of pandemic will become moderated on the brain cancer diagnostics market.

South and Central America Brain Cancer Diagnostics Strategic Insights

Strategic insights for the South and Central America Brain Cancer Diagnostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

South and Central America Brain Cancer Diagnostics Report Scope

South and Central America Brain Cancer Diagnostics Regional Insights

The geographic scope of the South and Central America Brain Cancer Diagnostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Brain cancer diagnostics market in South and Central America is expected to grow from US$ 69.7 million in 2021 to US$ 175.8 million by 2028; it is estimated to grow at a CAGR of 14.1% from 2021 to 2028. The term "primary brain tumor" refers to a tumor that begins in the brain. Cancer of the brain and nervous system is the tenth highest cause of mortality in men and women. In a person's lifetime, the chances of having this form of tumor are fewer than 1%. Most primary central nervous system (CNS) malignancies are brain tumors, which account for 85% to 90% of all cases. Brain tumors can be fatal, have a severe impact on quality of life, and ultimately transform a patient's and their family's lives.  Furthermore, early detection of tumors often provides more treatment options. Advanced imaging technology can pinpoint the location of brain tumors. Diagnostic tools include magnetic resonance imaging (MRI) and computed tomography (CT or CAT scan). Intraoperative MRI can also be used to guide tissue biopsy and tumor resection during surgery. Magnetic resonance spectroscopy (MRS) is used to examine the chemical characteristics of tumors. Thus, the increase in the prevalence of brain cancer highly demands brain cancer diagnostic tools.      

Key Market Segments

In terms of diagnostic type, the imaging test segment accounted for the largest share of the South and Central America brain cancer diagnostics market in 2020. In terms of cancer type, the glioblastoma multiforme segment accounted for the largest share of the South and Central America brain cancer diagnostics market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the South and Central America brain cancer diagnostics market in 2020.

Major Sources and Companies Listed

A few major primary and secondary sources referred to for preparing this report on the brain cancer diagnostics market in South and Central America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Thermo Fisher Scientific Inc., Siemens Healthineers A, GE Healthcare, Biocept, Inc., Koninklijke Philips N.V, Canon Medical Systems, Hitachi, Ltd., and Neusoft Medical Systems.

Reasons to buy report

• To understand the South and Central America Brain cancer diagnostics market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for South and Central America Brain cancer diagnostics market
• Efficiently plan M&A and partnership deals in South and Central America Brain cancer diagnostics market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form South and Central America Brain cancer diagnostics market
• Obtain market revenue forecast for market by various segments from 2021-2028 in South and Central America region.

South and Central America Brain Cancer Diagnostics Market Segmentation       

By Diagnostic Type

• Imaging Test
  • MRI
  • CT Scan
  • PET
• Biopsy
• Molecular Testing
• Lumbar Puncture
• Others

By Cancer Type

• Glioblastoma Multiforme
• Astrocytomas
• Ependymomas
• Others

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Country

• South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America

Companies Mentioned

1. Thermo Fisher Scientific Inc.
2. Siemens Healthineers A
3. GE Healthcare
4. Biocept, Inc.
5. Koninklijke Philips N.V
6. Canon Medical Systems
7. Hitachi, Ltd.
8. Neusoft Medical Systems